HotSheets by Year


Hot SHEET 2018

Made possible by charitable contributions from


 - Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Yearly Biopsy Not Needed for Prostate Cancer Surveillance
  • When PSA Is 4-10 ng/mL, phi Test Helps with Biopsy Decision
  • Cancer Survivors & PTSD
  • Phase 1 Trial of ProscaVax Vaccine Stopped PCa Progression
  • Amiloride for Managing Abiraterone-Induced Mineralocorticoid Excess
  • Doc Moyad’s No Bogus Science: "Low-Calorie Diet & Weight Loss"
  • Index of Medical Articles Published in the 2017 Us TOO Hot SHEET
  • Doctor Chodak’s Bottom Line
  • Existing Parasite Drug May Fight 8 Prostate and Colon Cancers
  • Enzalutamide Safe in Seizure-Prone Prostate Cancer Patients
  • Repeat Prostate Biopsies Do Not Raise Risk of Post-RP Complications
  • Metastasis-Directed Treatment Improves Progression-Free Survival
  • New Prostate Cancer Imaging Tracer
  • Doc Moyad’s No Bogus Science: “Exercise and the Risk of Dementia?”
  • Shorter but Higher Dose of RT Cuts Risk of Prostate Cancer Recurrence
  • Circulating Tumor Cell Count Predicts Overall Survival in Prostate Cancer
  • NCCN: Favorable vs. Unfavorable Intermediate-Risk Prostate Cancer
  • Safety Concerns with Trial of Xofigo/Zytiga Combination
  • Contemporary Incidence and Outcome of Lymph Node Metastases
  • Smaller Difference in PCa Death Risk Found Between RP & RT
  • Doctor Chodak’s Bottom Line
  • Focal Therapy for Primary Localized PCa Remains Investigational
  • Did They Die of Prostate Cancer?
  • Low PSA on ADT is Still Prognostic in New Treatment Era
  • Sildenafil for Penile Rehabilitation
  • Long-Term Antitumor Activity and Safety of Enzalutamide
  • Doc Moyad’s No Bogus Science: “Flu/Shingles Vaccine & Heart Attack?”
  • Physician Trust Tied to PSA Testing
  • Obese Men Have a Higher Risk of Post-RP Biochemical Recurrence
  • The Role of Lymph Node Dissection for Patients with Prostate Cancer
  • Routine Office Urine Culture Before Prostate Biopsy is Unnecessary
  • Doctor Chodak’s Bottom Line
  • Brachytherapy Boost Tops Surgery for Prostate Cancer
  • Single PSA Test Fails to Reduce Prostate Cancer Deaths
  • Imaging Agent Can Change Plans for Recurrent Prostate Cancer
  • No Definitive Link Between Physical Activity and Prostate Cancer
  • Novel PET Imaging Agent Detects Prostate Cancer Recurrence Early
  • Doc Moyad’s No Bogus Science: “Low-Fat vs. Low-Carb & Your Wallet?!”
  • Current PSA Monitoring Ignores Risk to Some Prostate Cancer Survivors
  • Liquid Biopsies Measuring Circulation Tumor DNA Not Ready for Prime Time
  • Hyperbaric Oxygenation Therapy to Preserve Post-RP Erectile Function
  • Doctor Chodak’s Bottom Line
  • Inclusion Criteria for Prostate Cancer Trials Inadvertently Exclude Blacks
  • Brachytherapy vs. Radical Prostatec-tomy in High-Risk Localized PCa
  • Higher Resource Use in mCRPC Patients Does Not Benefit Outcomes
  • FDA Approves Apalutamide for Non-metastatic Castrate-Resistant PCa
  • Higher RT Dose May Not Improve Prostate Cancer Outcomes
  • Digital Rectal Examination for Prostate Cancer Screening
  • Doc Moyad's No Bogus Science: – "Curcumin is Having a Good 2018?!"
  • QOL with Chemohormonal Treatment in Prostate Cancer
  • More High-Risk Prostate Cancer Now in the US Than Before
  • After Cancer, Accelerated Aging?
  • Diet, Exercise with Behavioral Counseling Can Reduce ADT Side Effects
  • Doctor Chodak’s Bottom Line
  • Nerve-Sparing Prostatectomy Does Not Benefit Everyone
  • USPSTF: Prostate Cancer Screen-ing Should be an Individual Decision
  • EBRT with Brachytherapy Matches Surgery for Prostate Cancer
  • Ultrahypofractionated RT for Prostate Cancer is Safe and Effective
  • Long-Term Outcomes of Adjuvant Treatment in High-Risk PCa
  • Doc Moyad’s No Bogus Science: “The Ripple Effect?!”
  • 4+3 vs. 3+4 PCa and Risk of Metastatic Disease at Time of Diagnosis
  • Predictors of Adverse Pathology After Radical Prostatectomy
  • PCa & Lung Cancers May Be #1 in HIV+ Subjects by Year 2030
  • Men Much Less Likely Than Women to Get BRCA Testing, Despite Risks
  • Doctor Chodak’s Bottom Line
  • No Survival Bump for Localized PCa with More Frequent PSA Tests
  • Notable Differences with Three Prostate Cancer Genomic Tests
  • Black Men Do Well in Prostate Cancer Trials
  • IsoPSA Test Could Reduce Overdiagnosis/Overtreatment in PCa
  • Laser Focal Ablation of Prostate Cancer Improves Outcomes
  • Doc Moyad’s No Bogus Science:- “Eight Glasses of Water Per Day?!”
  • No Immediate Treatment for Low-Risk Prostate Cancer
  • Prostate Cancer Survival Odds Worse for Smokers
  • This “Metastasis-Blocking” Compound Could Stop the Spread of Cancer
  • Abiraterone May Be More Effective in Black Men with Advanced PCa
  • Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
  • Doctor Chodak’s Bottom Line

CLICK HERE and opt-in to receive free educational emails from Us TOO.